Atlas Trials

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Clinical trial NCT04850040 · UNKNOWN

Trial details

NCT number
NCT04850040
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma Resectable
Start date
2021-05-06
Primary completion
2022-12-31
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.